ライフサイエンスコーパス: memantine

1 43 [59%] who continued donepezil and started memantine).

2 and 73 (25%) to continue donepezil and start memantine.

3 which could be normalized by treatment with memantine.

4 rological function of mice than did ACS48 or memantine.

5 ical neurons more markedly than did ACS48 or memantine.

6 N-methyl-d-aspartic acid receptor antagonist memantine.

7 tective use-dependent NMDAR channel blocker, memantine.

8 benzoic acid (ACS48) with a NMDAR antagonist memantine.

9 t memantine, or continue donepezil and start memantine.

10 or ACS48, but suppressed by memantine and S-memantine.

11 obtained by linking together galantamine and memantine.

12 hose posthypoxic rats injected with 30 mg/kg memantine.

13 steadiness with gabapentin and lethargy with memantine.

14 tases to HA-WBRT plus memantine or WBRT plus memantine.

15 ed the pro-aggressive effects of ketamine or memantine.

16 s 10 mg of memantine or (2) placebo vs 20 mg memantine.

17 pants were analyzed (alpha tocopherol = 140, memantine = 142, combination = 139, placebo = 140), with

18 SZ patients (n=18) and HS (n=14) received memantine 20 mg (p.o.) and placebo over 2 test days in a

19 r continue donepezil 10 mg per day and start memantine 20 mg per day, for 52 weeks.

20 t memantine, discontinue donepezil and start memantine 20 mg per day, or continue donepezil 10 mg per

21 Memantine (20 mg) significantly enhanced PPI in CPD subj

22 pride (400 mg), the NMDA receptor antagonist memantine (20 mg), or placebo.

23 Blocking NMDARs with memantine (30 mum) or GluN2B-containing receptors with i

24 festations," with greater frequencies in the memantine (31 events in 23 participants) and combination

25 reened, 81 were randomly assigned to receive memantine (39 patients) or placebo (42 patients).

26 tic trial of gabapentin (1,200mg/day) versus memantine (40 mg/day) for acquired nystagmus in 10 patie

27 42 [58%] who discontinued donepezil without memantine, 41 [54%] who discontinued donepezil and start

28 in patients who continued donepezil without memantine, 42 [58%] who discontinued donepezil without m

29 Patients were randomly assigned to a group: Memantine (5 mg/day) (n = 53) or Placebo (n = 75).

30 We randomly allocated 88 patients to receive memantine (72 [82%] had DAMES data and 75 [85%] had ABS

31 domly assigned to continue donepezil without memantine, 73 (25%) to discontinue donepezil without mem

32 e, 73 (25%) to discontinue donepezil without memantine, 76 (26%) to discontinue donepezil and start m

33 Memantine, a drug that blocks the ion channel formed by

34 Post-occlusion administration of memantine, a glutamate receptor antagonist that reduces

35 Low doses of memantine, a low to moderate affinity open channel uncom

36 Memantine, a medication for Alzheimer's disease, increas

37 Memantine, a NMDA receptor antagonist approved for treat

38 NitroSynapsin, but not the FDA-approved drug memantine, abrogated this hyperactivity.

39 Memantine acutely normalized cortical oscillatory dynami

40 itive low-affinity NMDA receptor antagonist, memantine, acutely increases electrophysiological measur

41 fter HA-WBRT plus memantine versus WBRT plus memantine (adjusted hazard ratio, 0.74; 95% CI, 0.58 to

42 In contrast, only memantine, administered systemically or intra-PLmPFC, in

43 l LTP, impairments that cannot be rescued by memantine administration.

44 ge depolarization nor maintained presence of memantine after agonist removal affected partial trappin

45 Administration of S-memantine after global cerebral ischemia and reperfusion

46 Incubation with S-memantine after reoxygenation following oxygen and gluco

47 cant reduction in only the 5.5 mm region and Memantine alone did not reach significance in either reg

48 nificant differences in the groups receiving memantine alone or memantine plus alpha tocopherol.

49 Memantine also inhibited Kir6.1 and Kir6.2 KATP channels

50 The structurally dissimilar NMDA antagonist memantine also reduced diabetic nephropathy, although it

51 Memantine, an adamantane derivative, has been used for t

52 We previously reported that memantine, an NMDA receptor antagonist, enhanced two bio

53 To test this hypothesis, the effect of memantine, an NMDA receptor antagonist, on the intensity

54 itory nerve compound action potential and/or Memantine, an NMDA receptor open channel blocker, would

55 totoxic insult and also to determine whether memantine, an NMDA-type glutamatergic channel blocker, i

56 Two key clinical trials of memantine and antioxidants for dementia in Down syndrome

57 Moreover, a combination of memantine and cDCS suppressed KA-induced seizures.

58 Two such agents, memantine and dextromethorphan, are already in widesprea

59 st that currently hypothesized mechanisms of memantine and ketamine action should be reconsidered and

60 hibition of distinct NMDAR subpopulations by memantine and ketamine and help to explain their differe

61 Both memantine and ketamine antagonize N-methyl-D-aspartate r

62 basic characteristics of NMDAR inhibition by memantine and ketamine appear similar, their effects on

63 Memantine and ketamine are clinically useful NMDA recept

64 ture drug development.SIGNIFICANCE STATEMENT Memantine and ketamine are NMDA receptor (NMDAR) channel

65 Therefore, differential inhibition by memantine and ketamine based on NMDAR location is likely

66 We found that memantine and ketamine differentially alter NMDAR desens

67 Equimolar memantine and ketamine had indistinguishable effects on

68 Here, we show that memantine and ketamine have contrasting effects on NMDAR

69 nefits of the glutamate receptor antagonists memantine and ketamine have helped sustain optimism that

70 N-methyl-D-aspartate (NMDA) antagonists like memantine and ketamine increase PPI, and under some cond

71 A prominent mechanistic difference between memantine and ketamine is the degree to which they are '

72 rch suggests that preferential inhibition by memantine and ketamine of distinct NMDAR subpopulations

73 en hypothesized to result from inhibition by memantine and ketamine of overlapping but distinct NMDAR

74 Memantine and ketamine, voltage- and activation-dependen

75 tions for differences between the effects of memantine and ketamine.

76 n the primary outcome, 6 weeks CMAI, between memantine and placebo (memantine lower -3.0; -8.3 to 2.2

77 sulfide (Na(2)S) or ACS48, but suppressed by memantine and S-memantine.

78 combined treatment with the NMDA antagonist memantine and the opioid antagonist naltrexone, when com

79 Rats received systemic Memantine and/or Piribedil for 3 days before and 3 days

80 completed the 1-year memantine trial (21 on memantine) and also completed longitudinal ERP studies w

81 (3-thioxo-3H-1,2-dithiol-4-yl)-ben zamide (S-memantine) and examined its effects in vitro and in vivo

82 [54%] who discontinued donepezil and started memantine, and 43 [59%] who continued donepezil and star

83 76 (26%) to discontinue donepezil and start memantine, and 73 (25%) to continue donepezil and start

84 ients with memory impairment (eg, donepezil, memantine, and ginkgo biloba), and bone marrow supportin

85 %, including the important drugs pregabalin, memantine, and the antimalarial artemisinin.

86 tagonist and antidepressant ketamine but not memantine, another NMDAR antagonist.

87 We confirmed that memantine antagonizes memory impairment in Alzheimer's m

88 the posthypoxic rats injected with 100mg/kg memantine are higher than those posthypoxic rats injecte

89 ether, these findings substantiate a role of memantine as a potential pharmacological treatment for b

90 Using such low dose of memantine as adjuvant treatment for improving cognitive

91 could contribute to the apparent benefits of memantine as an adjunctive treatment in schizophrenia, a

92 Patients assigned to receive memantine, as compared with those assigned to receive me

93 lts provide evidence of target engagement of memantine, as well as therapeutically relevant informati

94 ly enhanced in the treated group, indicating memantine-associated improvement in attentional processe

95 ptic hippocampal microcultures, we show that memantine at therapeutic concentrations (1-10 microM) pr

96 NPI mean difference favoured memantine at weeks 6 (-6.9; -12.2 to -1.6; p = 0.012) an

97 Memantine (at a dose of 20 mg/day) enhances the efficacy

98 Here, we report a novel target of the drug memantine, ATP-sensitive K(+) (KATP) channels, potential

99 The NMDA receptor antagonist memantine attenuates these effects.

100 ocal evidence to explain the tolerability of memantine based on differential extrasynaptic/synaptic r

101 Escitalopram/memantine-based remission, however, is characterized by

102 in, epicatechin, genistein, resveratrol, and memantine) before B(e)P exposure.

103 HA-WBRT plus memantine better preserves cognitive function and patien

104 In contrast, memantine binding increases occupancy of GluN1/2A and na

105 In the dog model, relative memantine bioavailability approaches 100% with sustained

106 ining 128 CAG repeats (YAC128) with low-dose memantine blocks extrasynaptic (but not synaptic) NMDARs

107 We found that memantine blocks extrasynaptic NMDAR-mediated currents i

108 For example, memantine but not ketamine may inhibit extrasynaptic NMD

109 e speed (p < 0.001), gabapentin by 32.8% and memantine by 27.8%, and improved visual acuity (p < 0.05

110 verge with a growing literature showing that memantine can enhance a range of metrics of auditory fun

111 Genistein, resveratrol, and memantine can reverse the apoptosis and oxidant producti

112 most promising preliminary evidence include memantine, carbamazepine, citalopram, and prazosin, but

113 nimals, showed increased motor activity on a memantine challenge (total distance traveled, 18.2 +/- 5

114 18)F-FDG brain uptake in a test, retest, and memantine-challenge study was measured in awake (n = 8)

115 this study, we recapitulate the ketamine and memantine clinical findings in mice, showing that ketami

116 s to escitalopram compared with escitalopram/memantine combination treatment display unique patterns

117 s more sensitive to blockade by ketamine and memantine compared to GluN1/2B in the presence of physio

118 ensitive to channel blockade by ketamine and memantine compared to GluN1/2B receptors in the presence

119 We noted no effect of patients starting memantine compared with not starting memantine during th

120 As a result, therapeutic memantine concentrations should have negligible effects

121 arly during the development of the pathology memantine confers neuronal and cognitive protection whil

122 Application of memantine/D-AP5 either produced a more uniform DCS-LTD t

123 e tested with application of NMDAR blockers (memantine/D-AP5).

124 a-NAcc shell, but not core, microinfusion of memantine decreased binge-like eating.

125 The efficacy of donepezil and of memantine did not differ significantly in the presence o

126 Memantine did not improve significant agitation in peopl

127 uced both appetitive and aversive PEs, while memantine diminished appetitive, but not aversive PEs.

128 es of ketamine or memantine, or infusions of memantine directly into the prelimbic (PLmPFC) or infral

129 out memantine, discontinue donepezil without memantine, discontinue donepezil and start memantine 20

130 to continue donepezil 10 mg per day without memantine, discontinue donepezil without memantine, disc

131 We found that memantine dissociation from NR1/2A receptors after agoni

132 NMDAR antagonist, clinical data suggest that memantine does not exert rapid antidepressant actions fo

133 signaling coupled to NMDAR at rest, in that memantine does not inhibit the phosphorylation of eukary

134 Memantine dose-dependently decreased binge-like eating a

135 tarting memantine compared with not starting memantine during the first year (0.92 [0.58-1.45]) or th

136 ppocampal neurons, we show that ketamine and memantine effectively block NMDAR-mediated miniature exc

137 At therapeutic concentrations, memantine effectively blocks excessive extrasynaptic NMD

138 DAR antagonist or systemic administration of memantine effectively reversed nociceptive and mechanica

139 Memantine effects on functional measures of auditory dis

140 Here, we describe memantine effects on gammaEP and gammaPL in those subjec

141 ts, significant correlations between age and memantine effects were detected for gammaEP and gammaPL:

142 SZ patients had reduced gammaEP and gammaPL; memantine enhanced gammaEP and gammaPL (p<0.025 and 0.00

143 ine increase PPI, and under some conditions, memantine enhances MMN; these findings present a challen

144 age) were treated for 3 months with doses of memantine equivalent to those used in humans.

145 g that partial trapping does not result from memantine escape through open channels.

146 Animals not receiving memantine exhibited significantly lower mfVEP amplitudes

147 This differential effect of ketamine and memantine extends to intracellular signaling coupled to

148 pharmacological candidates in this group and memantine for neuropsychiatric symptoms.

149 Five participants in the memantine group and four controls died from serious adve

150 10 (11%) of 88 participants in the memantine group and six (7%) of 85 controls had serious

151 lly well tolerated; however, patients in the memantine group had more frequent cognitive adverse even

152 In the memantine group, these scores declined 1.98 units less (

153 mory performance after one year only for the memantine group.

154 After 12 weeks, Memantine-group required a somewhat lower methadone dose

155 Intra-ILmPFC memantine had no effect on aggression in either AHAs or

156 Memantine had no effect on these parameters in wild-type

157 at it still remains to be determined whether memantine has a role in milder agitation in AD.

158 Memantine has been used off-label to treat frontotempora

159 ings in mice, showing that ketamine, but not memantine, has antidepressant-like effects in behavioral

160 The NMDA antagonist, memantine, has dose-dependent effects on preconscious, a

161 herapeutic drug efficacy and tolerability of memantine have been attributed to fast kinetics and stro

162 Although vitamin E and memantine have been shown to have beneficial effects in

163 Memantine, however, induces far fewer behavioural side-e

164 rescription of a cholinesterase inhibitor or memantine hydrochloride from the Danish National Prescri

165 This formulation of memantine hydrochloride is the first oral dosage form th

166 Acetylcholinesterase inhibitors and memantine hydrochloride were introduced in 61 (65.6%) pa

167 e (donepezil, galantamine, rivastigmine, and memantine) improved scores on the ADAS-Cog 11 by 1 to 2.

168 s on these measures might suggest a role for memantine in augmenting the cognitive and functional imp

169 substudy of the randomized clinical trial of memantine in FXTAS sought to use the N400 repetition eff

170 Application of memantine in isolation was associated with a dose-depend

171 rolled trial of escitalopram or escitalopram/memantine in late-life depression with subjective memory

172 uble-blind, placebo-controlled Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOM

173 We provide evidence of the benefit of add-on memantine in opioid dependent patients undergoing MMT.

174 stic explanation for the limited efficacy of memantine in preventing memory loss in AD.

175 functional differences between ketamine and memantine in their ability to block NMDAR function at re

176 Some monkeys received memantine in their diet before and after ExpG induction

177 uggested that, compared with placebo, add-on memantine inconsistently improved cognition and improved

178 f IP ketamine, IP memantine, or intra-PLmPFC memantine increased aggression in AHAs, but only in the

179 Memantine increased CaMKII activity in the APP23 mouse h

180 S-memantine increased intracellular sulfide levels in huma

181 The increased memantine-induced (18)F-FDG uptake was more pronounced i

182 Ongoing studies will determine whether these memantine-induced changes predict acute pro-cognitive or

183 activity in the APP23 mouse hippocampus, and memantine-induced enhancement of hippocampal long-term p

184 deling showed that the voltage dependence of memantine inhibition also is altered by 1 mM Mg(2+)(o).

185 In contrast, memantine inhibition of the other principal NMDAR subtyp

186 centrations, the genistein, resveratrol, and memantine inhibitors were able to reverse significantly

187 ffect after infusion of the NMDAR antagonist memantine into the nucleus accumbens and ventral tegment

188 We aimed to determine whether memantine is an effective treatment for FTD.

189 Memantine is an N-methyl-d-aspartate receptor antagonist

190 th Alzheimer's drugs is inadequate, although memantine is beneficial in transgenic mice.

191 Despite promising indications, memantine is not an effective treatment.

192 We tested the primary hypothesis, memantine is superior to placebo for clinically signific

193 6 weeks CMAI, between memantine and placebo (memantine lower -3.0; -8.3 to 2.2, p = 0.26); or 12 week

194 These findings indicate that memantine may benefit attentional processes that represe

195 The superficial binding site for memantine may, by causing partial trapping, contribute t

196 y) + placebo memantine, or NTX (50 mg/day) + memantine (MEM; 20 mg/day), during the first treatment p

197 treatment in schizophrenia, and suggest that memantine might augment learning and potentially clinica

198 erformance in opioid dependents; the dose of memantine might be a worthy topic in future studies.

199 Low-dose memantine might have anti-inflammatory and neurotrophic

200 both approach and avoidance learning, while memantine mildly attenuated approach learning but had no

201 domly assigned to the experimental (5 mg/day memantine (MMT+M) or placebo (MMT+P) group: 57 in MMT+M,

202 Memantine modestly enhanced functional measures of audit

203 Altogether, our studies show that memantine modulates Kir6.2 activity, and that the Kir6.2

204 d before agonist removal, whereas some bound memantine molecules dissociate after agonist removal, a

205 /d of alpha tocopherol (n = 152), 20 mg/d of memantine (n = 155), the combination (n = 154), or place

206 ety of other agents (eg, riluzole, ketamine, memantine, N-acetylcysteine, lamotrigine, celecoxib, ond

207 f tropisetron to the current AD therapeutics memantine (Namenda) and donepezil (Aricept), using simil

208 As a result, inhibition by memantine of GluN1/2A receptors in tsA201 cells and of n

209 get glutamate neuronal transmission, such as memantine, offer a novel approach to the treatment of la

210 , we examined the effects of NMDA antagonist memantine on attention and working memory.

211 We aimed to assess safety and efficacy of memantine on cognition and function in individuals with

212 Then, we tested the effects of memantine on food-seeking behavior, under a second-order

213 Finally, we evaluated the effects of memantine on FR1 responding for food, when microinfused

214 ences between the efficacies of ketamine and memantine on NMDAR-mediated neurotransmission that have

215 f the uncompetitive NMDA receptor antagonist memantine on palatable food-induced behavioral adaptatio

216 e assessed for the first time the effects of memantine on PPI and MMN in CPD subjects.

217 discontinuation of donepezil and starting of memantine on subsequent nursing home placement in patien

218 of food responding, we tested the effects of memantine on the Chow and Palatable food groups' intake.

219 Furthermore, we investigated the effects of memantine on the intake of food when it was offered in a

220 The effects of memantine on these parameters were investigated.

221 n, comparing either: (1) placebo vs 10 mg of memantine or (2) placebo vs 20 mg memantine.

222 because of many patients' preference to take memantine or cholinesterase inhibitors off-label rather

223 als were randomly assigned to receive either memantine or matched placebo tablets (1:1) in blocks of

224 omly allocated participants (1:1) to receive memantine or placebo for 52 weeks by use of a computer-g

225 on corticosteroid therapy were randomized to memantine or placebo in a double-blind, crossover design

226 tients with brain metastases to HA-WBRT plus memantine or WBRT plus memantine.

227 e donepezil, discontinue donepezil and start memantine, or continue donepezil and start memantine.

228 intraperitoneal (i.p.) doses of ketamine or memantine, or infusions of memantine directly into the p

229 Moderate doses of IP ketamine, IP memantine, or intra-PLmPFC memantine increased aggressio

230 either naltrexone (NTX; 50 mg/day) + placebo memantine, or NTX (50 mg/day) + memantine (MEM; 20 mg/da

231 benefits of the combination of donepezil and memantine over donepezil alone.

232 roaches 100% with sustained plasma levels of memantine over seven days and profiles that can be tuned

233 Additional studies of memantine, perhaps in combination with other therapeutic

234 , as compared with those assigned to receive memantine placebo, had a score on the SMMSE that was an

235 s in the groups receiving memantine alone or memantine plus alpha tocopherol.

236 art, after ingesting either placebo or 20 mg memantine po, in a double-blind, within-subject cross-ov

237 er the clinically tolerated NMDAR antagonist memantine possesses antidepressant properties.

238 Finally, memantine pre-incubation prevented Abeta-induced inhibit

239 We previously showed that memantine preferentially blocked neurotoxicity mediated

240 S-memantine prevented glutamate-induced glutathione deplet

241 reover, NMDA receptor antagonists MK-801 and memantine prevented seizure-related SD and apnea, which

242 (2)S-releasing NMDAR antagonist derivative S-memantine prevents ischemic neuronal death, providing a

243 Memantine, previously reported as neuroprotective may at

244 quilibration for the two compounds, although memantine produced a more prominent fast component (62%

245 Combined treatment with Piribedil and Memantine produced a significant reduction in the noise-

246 We investigated whether add-on memantine reduced cytokine levels and benefitted patient

247 all data, patients who received HA-WBRT plus memantine reported less fatigue (P = .04), less difficul

248 on compound related to the FDA-approved drug memantine, representing an uncompetitive/fast off-rate a

249 Memantine rescued both neuronal oxidative stress and the

250 atment for 2 weeks with an NMDAr antagonist (memantine) rescued cerebrovascular expression of claudin

251 genous NMDAR channel blocker that binds near memantine's binding site.

252 Research on memantine's mechanism of action has focused on the NMDAR

253 , by causing partial trapping, contribute to memantine's unique therapeutic utility.

254 re detected for gammaEP and gammaPL: greater memantine sensitivity on gammaEP and gammaPL were presen

255 ther NMDA open channel blockers ketamine and memantine showed a similar effect.

256 ound that a neuroprotective concentration of memantine shows little selectivity for extrasynaptic NMD

257 Cholinesterase inhibitors and memantine slightly reduced short-term cognitive decline,

258 ntially alter NMDAR desensitization and that memantine stabilizes a Ca(2+)-dependent desensitized sta

259 Meta-analysis of memantine suggested that it is well tolerated but with f

260 ble-blind, placebo-controlled trial of 20 mg memantine taken orally daily for 26 weeks in patients wi

261 A3 region was significantly larger following memantine than placebo (p = .011).

262 protection from Abeta-induced apoptosis than Memantine, the most recently FDA-approved drug for AD tr

263 difference in IOP elevation exposure between memantine-treated and no-memantine-treated monkeys.

264 lum did not differ significantly between the memantine-treated and the saline-treated posthypoxic rat

265 ExpG eyes from memantine-treated animals had higher overall mean amplit

266 After the treatment, memantine-treated mice had restored cognition and signif

267 on exposure between memantine-treated and no-memantine-treated monkeys.

268 Memantine treatment also was associated with a decline i

269 Memantine treatment had no effect on either the NPI (mea

270 Importantly, memantine treatment is able to partially normalize infor

271 These results suggest that memantine treatment may have beneficial effects on verba

272 Analysis also revealed that memantine treatment normalized the P2 habituation effect

273 These results suggest that the effects of memantine treatment on AD brain include disease modifica

274 tition effect to evaluate effects of chronic memantine treatment on verbal memory.

275 Memantine treatment showed no benefit in patients with F

276 genesis after stroke by physical activity or memantine treatment weakened existing memories.

277 ppocampal regions and if this is modified by memantine treatment.

278 appear to carryover after discontinuation of memantine treatment.

279 ta from 41 patients who completed the 1-year memantine trial (21 on memantine) and also completed lon

280 in each arm) who completed both the primary memantine trial and two EEG recordings (at baseline and

281 There are no memantine trials in clinically significant agitation but

282 The combination of 5al, donepezil, and memantine (triple combination) produces synergistic effe

283 These data do not support memantine use in FTD.

284 s donepezil for mild to severe dementia, and memantine (used alone or as an add-on therapy) for moder

285 ed trial and 149 people started the trial of memantine versus placebo.

286 e was significantly lower after HA-WBRT plus memantine versus WBRT plus memantine (adjusted hazard ra

287 al clinical trial investigated the effect of memantine vs. placebo on hippocampal subfield volume in

288 Based on these results, oral memantine was administered to both children, with result

289 Memantine was also applied in isolation to characterize

290 n=17) and WT (n=17) oocytes, block by 10 muM memantine was also reduced (mean 26% [6] vs 75 [7], p<0.

291 Coapplication of memantine was associated with recovery of RGC tonic spik

292 For each condition, memantine was coapplied to determine its efficacy for re

293 Memantine was generally well tolerated; however, patient

294 Finally, the NMDA-R antagonist memantine was protective against the manifestation of sy

295 Memantine was significantly better than placebo for cogn

296 S-memantine was synthesized by chemically combining a slow

297 Memantine was the most potent and genistein was the leas

298 harmacological approaches with Ro25-6981 and memantine, we provide evidence suggesting that chronic e

299 scores for the posthypoxic rats treated with memantine were significantly higher than those treated w

300 By contrast, high-dose memantine, which blocks both extrasynaptic and synaptic